LMB64 Bacterial Extracts for Inflammatory Disorder Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for chronic intestinal inflammatory disorders like Crohn's disease and periodontitis are costly and inefficient, with existing therapies targeting immunological and inflammatory pathways but lacking effective, cost-friendly alternatives.
Innovation Solution
Isolation and characterization of a novel bacterial strain, LMB64, belonging to the Betaproteobacteria class, which is nonpathogenic and can be cultured in ordinary water, leading to the development of bacterial extracts that modulate immune responses, activate Toll-like receptors, and act as a PAR2 antagonist, providing a cost-effective treatment for inflammatory disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If monoclonal antibodies (anti-TNF, anti-IL-12/p40 or anti-IL-23/p40) are used to treat Crohn's disease, then therapeutic effectiveness is improved, but treatment cost increases significantly
Solution Approach 1:
The patent employs a bacterium (Lactobacillus paracasei subsp. paracasei 04) as a cheap, renewable biological source that produces anti-inflammatory compounds in vivo, replacing expensive monoclonal antibodies with a cost-effective probiotic therapy that continuously generates therapeutic substances within the patient's gut microbiota
Solution Approach 2:
The probiotic bacterium serves as a self-sustaining therapeutic system that colonizes the gut and autonomously produces anti-inflammatory metabolites and modulates the immune system without requiring external administration of expensive drugs, making the treatment system self-regulating and cost-efficient
2Object-affected harmful factors
If existing immunological therapies are used for chronic intestinal inflammatory disorders, then inflammatory responses are targeted, but treatment efficiency is insufficient
Solution Approach 1:
The patent introduces a probiotic bacterium as a biological intermediary that mediates between the host immune system and the inflammatory environment, producing metabolites like butyrate and modulating immune cell activity to achieve more effective anti-inflammatory outcomes than direct immunosuppressive therapy
Solution Approach 2:
The therapy changes the compositional parameters of the gut microbiota by introducing specific probiotic strains that alter metabolic profiles and immune modulation capabilities, transforming the therapeutic mechanism from external drug administration to internal microbial-mediated immune regulation
Data Source
Figure 1
Figure 2A~2B
Figure 3
AI summary
The present invention relates to a novel bacterial strain isolated and characterized from groundwater. The invention also relates to bacterial extracts and to the therapeutic use of same, notably in the context of the treatment of inflammations.